George Pentheroudakis: We propose a research and regulatory framework for validation/graduation of tumour-agnostic therapies and biomarkers
George Pentheroudakis, Chief Medical Officer at ESMO, shared the following post by Vivek Subbiah on X, adding the following:
“Following a drug screening positive by ETAC-S, we propose a research and regulatory framework for validation/graduation of tumour-agnostic therapies and biomarkers.”
Quoting Vivek Subbiah’s post:
“Proposed tumour-agnostic drug development framework considering the deployment of efficient modern trial designs and streamlined regulatory processes which can exploit targeted driver molecular aberrations across tumour types.”
Read Vivek Subbiah’s thread in its entirety for additional insights.
Source: George Pentheroudakis/X and Vivek Subbiah/X
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.
He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023